When cancer dials a wrong number; Do allergies lower risk of brain cancer?;

> When cancer dials a wrong number: genetic copy number variations (CNVs) could be biomarkers in testicular cancer but not in breast or colon cancers. Press release | Abstract | Article

> The protein transient receptor potential melastatin-like 7 (TRPM7) predicts breast cancer cell metastasis and poor outcome, and has potential as part of a prognostic panel. Press release | Abstract

> Foundation Medicine and Clovis Oncology have signed a diagnostic collaboration to identify biomarkers, hoping to create a diagnostic to select cancer patients most likely to respond to Clovis' rucaparib, a PARP inhibitor in Phase I/II. Press release

> Mayo Clinic has completed the first genome-wide analysis of peripheral T-cell lymphomas and identified 13 novel alterations. Press release | Abstract

> Vermillion's shares jumped almost 6% on the positive clinical trial results from its OVA1 ovarian cancer blood test. Article | Press release

> Endocannabinoids in saliva could be a biomarker of obesity. Abstract

> According to Chinese researchers, XAF1 could be used as a biomarker to differentiate between liver cancer and healthy tissue. Abstract

> Biomarker validation company Abcodia has appointed Claire Hooper as a non-executive director of the board. Press release

And Finally… Could a sneeze cut your risk of brain cancer? Maybe hay fever's not so bad--people with allergies seem to be at lower risk of glioma. Press release | Abstract

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.